Single-arm, open-label, multicentre phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) in combination with vinorelbine for the treatment of patients with metastatic breast cancer with intermediate HER2 expression (HER2 2+ by immunohistochemistry, fluorescence in-situ hybridisation (FISH) negative) after failure of first-line therapy in the metastatic setting and having been pre-treated with anthracyclines - BIBW 2992 (Afatinib) and vinorelbine

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2011
This article has no abstract
Epistemonikos ID: d3293af839d19cc1338dd0aee44e4ab985a71c7d
First added on: Apr 17, 2025